TEVA Pharmaceutical Industries (TEVA) cash: $3.6B
TEVA Pharmaceutical Industries held $3.6B in cash and cash equivalents on Dec 31, 2025, up 7.8% from $3.3B a year earlier.
From TEVA Pharmaceutical Industries's filings with the SEC · Read the filing · TEVA stock page
TEVA Pharmaceutical Industries cash by year
#174 of 4,171 US companies by cash · See the full ranking
| Year ended | Cash | Change |
|---|---|---|
| Dec 31, 2025 | $3.6B | +8% |
| Dec 31, 2024 | $3.3B | +2% |
| Dec 31, 2023 | $3.2B | +15% |
| Dec 31, 2022 | $2.8B | +29% |
| Dec 31, 2021 | $2.2B | – |
Cash of similar companies
Companies in the same industry as TEVA Pharmaceutical Industries, by SEC industry code, with the closest cash. Each name opens the same page for that company.
| Company | Cash, latest year | Year ended |
|---|---|---|
| Eli Lilly | $7.3B | Dec 31, 2025 |
| AbbVie | $5.2B | Dec 31, 2025 |
| Vertex Pharmaceuticals Inc / Ma | $5.1B | Dec 31, 2025 |
| BeOne Medicines | $4.5B | Dec 31, 2025 |
| TEVA Pharmaceutical Industries | $3.6B | Dec 31, 2025 |
| Regeneron Pharmaceuticals | $3.1B | Dec 31, 2025 |
| Zoetis | $2.5B | Dec 31, 2025 |
Questions and answers
What is TEVA Pharmaceutical Industries's cash?
TEVA Pharmaceutical Industries held $3.6B in cash and cash equivalents on Dec 31, 2025, up 7.8% from $3.3B a year earlier.
Numbers as reported in TEVA Pharmaceutical Industries's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology